EUCTR2006-002366-18-IT进行中（未招募）不适用
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in the Elderly - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 3,655
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Aged over 60 years on the day of inclusion 2 Informed Consent Form signed 3 Able to attend all scheduled visits and to comply with all trial procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances 2 Febrile illness oral temperature 8805; 37.5 C or rectal equivalent temperature 8805; 38.0 C on the day of inclusion 3 Participation in another clinical trial in the four weeks preceding the first trial vaccination 4 Planned participation in another clinical trial during the present trial period 5 Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy 6 Unstable chronic illness defined as illness requiring hospitalization or a clinically significant change in medication in the 12 weeks prior to inclusion at a stage that could interfere with trial conduct or completion 7 Current abuse of alcohol or drug addiction that may interfere with the subject s ability to comply with trial procedures 8 Blood or blood-derived products received in the past 3 months 9 Any vaccination in the 4 weeks preceding the first trial vaccination 10 Vaccination planned in the 4 weeks following the first trial vaccination 11 Previous vaccination against influenza in the previous 6 months with the trial vaccine or another vaccine 12 Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination 13 Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in the Elderly.Vaccination of elderly subjects aged 60 years and over with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.EUCTR2006-002366-18-LTSanofi Pasteur SA3,655
进行中（未招募）
不适用
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in the Elderly.EUCTR2006-002366-18-BESanofi Pasteur SA3,655
进行中（未招募）
1 期
Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in 50 to 59 Years old AdultsVaccination of adults subjects aged 50 to 59 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.EUCTR2008-001219-39-NLSanofi Pasteur SA2,740
进行中（未招募）
不适用
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)EUCTR2008-000943-33-GBSanofi Pasteur SA
进行中（未招募）
不适用
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the new formulation of the influenza vaccine for the 2007-2008 Northern Hemisphere season.EUCTR2007-000752-14-GBSanofi Pasteur SA